

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED**

**中國神威藥業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2877)**

**2023 INTERIM RESULTS ANNOUNCEMENT**

The board of directors (the “Board”) of China Shineway Pharmaceutical Group Limited (the “Company” or “Shineway”) is pleased to present the unaudited consolidated results of the Company and its subsidiaries (collectively the “Group”) for the six months ended 30 June 2023 (the “Period”) as follows:

**FINANCIAL HIGHLIGHTS**

For the six months ended 30 June 2023 (the “Period”), the operating results of the Group were as follows:

- Turnover amounted to RMB2,398,680,000, an increase of 32.1% as compared to the corresponding period of last year;
- Gross profit margin was 75.2% as compared to 73.0% of the corresponding period of last year;
- Profit for the Period amounted to RMB491,465,000, an increase of 48.4% as compared to the corresponding period of last year;
- Earnings per share amounted to RMB65 cents, an increase of 47.7% as compared to the corresponding period of last year;
- Declared 2023 second interim dividend of RMB11 cents per share;
- Net assets per share amounted to RMB8.03 (equivalent to HKD8.70); and
- Net cash per share amounted to RMB6.49 (equivalent to HKD7.03).

## **BUSINESS REVIEW**

### **A New High on Sales Again for the Interim Results**

The PRC government continued to introduce policies to strengthen and optimize the environment for the development of traditional Chinese medicine (“TCM”), to support the high-quality development of TCM industry, and to vigorously promote the inheritance and innovation of TCM. While embracing industrial development opportunity, the Group strengthened the introduction of scientific and technological innovation and continuously increased investment in scientific research. The Group has actively carried on the development of digital and intelligent supply-chain projects, promoted the deep integration of TCM and modern science and technology, and gave full play to the unique advantages of TCM with the support of innovation. Meanwhile, the Group has continuously stepped up its evidence-based medical research for products, increased terminal coverage as well as academic promotion, and also actively promoted quality improvement and efficiency enhancement, with the aim of enhancing operational efficiency and promoting the continuous growth of its operating results.

For the six months ended 30 June 2023 (the “Period”), the Group’s sales increased by 32.1% as compared to the same period of last year to RMB2,398,680,000, which was a new record high for interim sales results. Net profit increased by 48.4% to RMB491,465,000. Earnings per share also increased by 47.7% to RMB65 cents as compared to the same period last year.

The rapid growth of net profit was mainly due to the notable increase in overall sales volume of each dosage form, as well as the increases in both gross profit margin and net profit margin. During the Period, driven by the effect of economies of scale from higher overall production and the effectiveness of the Group’s efforts to improve quality and efficiency, gross profit margin increased from 73.0% to 75.2%. On the other hand, sales and distribution costs and administrative expenses increased only by 24.3% and 8.1% respectively as compared with the same period last year, resulting in an increase in net profit margin from 18.2% to 20.5%.

The Board of the Group resolved to declare the second interim dividend in respect of the fiscal year 2023 of RMB11 cents per share, which will be paid on 29 September 2023 to the shareholders whose names appear on the Company’s register of members on 15 September 2023.

As of 30 June 2023, calculating based on the total issued shares of 827,000,000, net cash per share of the Group amounted to HKD7.03, and net assets per share amounted to HKD8.70.

## Each Dosage Form Delivered Excellent Results

After the pandemic, the Group made every effort to strengthen terminal coverage and academic promotion. Each dosage form delivered excellent results during the Period. The table below shows the overall sales and growth rates of each dosage form for the first half of 2023 as compared to the same period last year:

	Sales First six months of 2022	Sales <b>First six months of 2023</b>	Period-on- period growth rate	Percentage of sales First six months of 2023
Injection products	697,146	<b>957,253</b>	37.3%	39.9%
Soft capsule products	295,959	<b>352,066</b>	19.0%	14.7%
Granule products	257,806	<b>331,191</b>	28.5%	13.8%
TCM formula granules	469,273	<b>628,658</b>	34.0%	26.2%
Other product formats	95,010	<b>129,512</b>	36.3%	5.4%
Oral products	<u>1,118,048</u>	<u><b>1,441,427</b></u>	<u>28.9%</u>	<u>60.1%</u>
Total sales	<u>1,815,194</u>	<u><b>2,398,680</b></u>	<u>32.1%</u>	<u>100.0%</u>

The Group continued to focus on the development strategy of oral products. Overall sales of oral products increased by 28.9% in the first six months of 2023, of which sales of soft capsules, granules and TCM formula granules increased by 19.0%, 28.5% and 34.0% respectively, as compared to the same period last year. The increase in soft capsule products and granule products was mainly driven by the Group's exclusive oral products such as Huamoyan Granule, Huamoyan Capsule, Qi Huang Tong Mi Granule, Jiang Zhi Tong Luo Soft Capsule and exclusive oral dosage form products such as Qing Kai Ling Soft Capsule and Huo Xiang Zheng Qi Soft Capsule. At the same time, driven by prescription medications for respiratory system such as Qing Kai Ling Injection, and cardiovascular and cerebrovascular prescription medications such as Shen Mai Injection and Guan Xin Ning Injection, injection products of the Group recorded a total growth of 37.3%.

## Essential Drugs – Sales Increased by 57.0%

The Group regularly manufactured a total of 18 medications which are listed on the National Essential Drug List, including Qing Kai Ling Injection, Shen Mai Injection, Qing Kai Ling Soft Capsule, Huamoyan Granule, Huo Xiang Zheng Qi Soft Capsule, Compound Licorice Tablet and so on. During the Period, the overall sales of the Group's regularly-manufactured medications listed on the National Essential Drug List increased by 57.0% to RMB928,912,000, accounting for 38.7% of the Group's overall sales, of which 77.0% were prescription medications, while 23.0% were OTC medications ("OTC Medications").

According to national policies, the essential drugs shall be prioritized for treatments in medical institutions at all levels and the proportion of use of essential drugs shall be increased. In particular, the proportion of essential drugs by number of types in primary public medical and healthcare institutions, second-tier public hospitals and third-tier public hospitals, should be no less than 90%, 80% and 60% respectively in principle, and medical institutions at all levels are required to follow the “1+X” protocol with essential drugs as the lead.

The government’s promotion of the widespread use of essential drugs will drive the sustained growth of the Group’s prescription medications and OTC Medications which are included in the National Essential Drug List.

### **Prescription Medications – Sales Increased by 27.2%**

For the six months ended 30 June 2023, the sales of the Group’s prescription and OTC medications accounted for approximately 85.7% and 14.3% of the Group’s total sales respectively.

During the Period, the overall sales of prescription medications increased by 27.2% as compared to the same period last year. The table below summarizes the growth of the Group by medicine category:

	Sales First six months of 2022	Sales First six months of 2023	Percentage of sales	Sales growth First six months of 2023
<i>RMB’000</i>				
TCM formula granules	469,273	<b>628,658</b>	26.2%	34.0%
Respiratory system prescription medications	281,823	<b>512,898</b>	21.4%	82.0%
Cardio-cerebrovascular injection prescription medications	439,625	<b>498,150</b>	20.8%	13.3%
Exclusive oral prescription medications	194,586	<b>229,793</b>	9.5%	18.1%
Other prescription medications	231,870	<b>187,350</b>	7.8%	-19.2%
Prescription medications	1,617,177	<b>2,056,849</b>	85.7%	27.2%
OTC medications	198,017	<b>341,831</b>	14.3%	72.6%
Total sales	<u>1,815,194</u>	<u><b>2,398,680</b></u>	<u>100.0%</u>	<u>32.1%</u>

## **TCM Formula Granules - Opportunities of Accelerating the Development of Market Opening**

The Group's TCM formula granules continued to grow rapidly with sales surging by 34.0% during the Period, accounting for 26.2% of the Group's total sales. The Group is now ranked among the top five listed companies in China in terms of sales of TCM formula granules.

During the Period, the Group's TCM formula granules team continued to step up its efforts in the market development and personnel deployments of graded medical institutions and grass-root markets in Hebei, Yunnan and other provinces. Currently, Class III hospitals in Hebei and Yunnan Provinces contributed to the majority of the sales of TCM formula granules of the Group, accounting for 83.1% of the total sales of TCM formula granules. During the Period, the Group's sales in grass-root medical institutions in provinces including Hebei, Yunnan and other provinces across the country accounted for 16.9% of the total sales of TCM formula granules.

As of 30 June 2023, the National Medical Products Administration and the Chinese Pharmacopoeia Commission had promulgated national standards for a total of 248 varieties of TCM formula granules. On 15 August 2023, the Chinese Pharmacopoeia Commission issued the "Notice on the Transmission of the Fifth Batch of 25 National Standards for TCM Formula Granules" (《關於轉發第五批25個中藥配方顆粒國家標準的通知》), which announced 17 new national standard varieties and 8 revised varieties. This brings a total of 256 varieties of TCM formula granules now on the national standards list. The Group will complete all filings for the listing of the fifth batch of 25 national standard varieties recently announced as soon as possible.

At present, the Group has completed the listing on the online procurement portals for the types of TCM formula granules that comply with both the national and provincial quality standards in 13 provinces and municipalities, including Beijing and Tianjin, Hebei, Yunnan, Anhui, Fujian, Shandong, Gansu, and Inner Mongolia. In the second half of 2023, the Group's TCM formula granules business unit will accelerate the development work of graded medical institutions in Beijing, Tianjin, Shandong and Anhui and the grass-root market across the country.

On 17 August 2023, the Shandong Public Resources Trading Centre released the "Centralized Procurement Documents for the Procurement Alliance of TCM Formula Granules (Consultation Draft)" stipulating a total of 15 provincial units including Shandong, Shanxi, Inner Mongolia, Liaoning, Jilin, Heilongjiang, Anhui, Jiangxi, Hainan, Yunnan, Tibet, Shaanxi, Qinghai, and Xinjiang form a provincial alliance to commence the centralized procurement of 200 varieties that comply with national drug standards of TCM formula granules. The launch of the centralized procurement by the provincial alliance may become a catalyst opportunity for the Group to accelerate the development of TCM formula granule market in the provincial alliance.

The Group's production capacity of TCM formula granules has reached an annual production value of RMB5 billion. In the future, the Group will continue to implement its production capacity expansion plan based on market development status.

## **Respiratory System Prescription Medications – Demand Exceeding Supply**

The Group’s respiratory system prescription medications soared in sales by 82.0% during the Period and recorded total sales of RMB512,898,000, accounting for 21.4% of the overall sales of the Group. Among them, Qing Kai Ling Injection recorded sales of RMB400,632,000 for the Period, representing an increase of 92.8% and accounting for 16.7% of the overall sales of the Group. Qing Kai Ling medication mainly treats high fever, viral cold, and respiratory tract infections. Qing Kai Ling Injection has been listed on the National Essential Drug List and the National Reimbursement Drug List. It is an “Essential Drug for the Emergency Department of TCM Hospital” recognized by the National Administration of TCM, and is also listed on the “Consensus of TCM Treatment Experts on Human Infection with H7N9 Avian Influenza (2014 Edition)” and the “Type A H1N1 Influenza Diagnosis and Treatment Program” by the state. During the COVID-19 pandemic, several provinces included Qing Kai Ling injection in the recommended medicine catalogue of their treatment programs. As an anti-influenza drug recommended by national institutions, there is a vast demand for Qing Kai Ling Injection. In early 2023, there was a high incidence of influenza in China, during which the demand for Qing Kai Ling Injection was far exceeding its supply.

## **Chinese Medicine Injections Prescription Medications for Cardiovascular and Cerebrovascular Diseases – Riding on the Accelerating Trend of Aging Population**

The state has gradually lifted the reimbursement restrictions of medical insurance on Chinese medicine injections, and several Chinese medicine injections varieties were selected into the diagnosis and treatment plan for Novel Coronavirus Pneumonia recommended by the national institutions. In recent years, a number of Chinese medicine injections have been included in the scope of centralized procurement for use in public medical institutions at all levels across the country and many provinces. Such positive factors have led to a recovery in the demands for Chinese medicine injection.

Chinese medicine injections not only preserve the characteristics of TCM, but also have the advantages of rapid action profile of western medicines. Their advantages such as targeted efficacy and acupoint injection can effectively make up for the shortcomings of other dosage forms of TCM while Chinese medicine injections also have the characteristics of high-level drug bioavailability, remarkable efficacy, etc..

In recent years, the Group’s Qing Kai Ling Injection, Shen Mai Injection, Shu Xue Ning Injection and Guan Xin Ning Injection won the bid in each of the national and provincial centralized TCM procurements. During the Period, overall sales of the Group’s injection products increased by 37.3%. In particular, on top of a 92.8% increase in the respiratory system medication Qing Kai Ling Injection, the Group recorded a 13.3% increase in a series of cardiovascular and cerebrovascular TCM injection prescriptions to RMB498,150,000. Sales of Shen Mai Injection and Guan Xin Ning Injection increased by 22.6% and 29.1% to RMB111,129,000 and RMB203,604,000 respectively, and sales of Huang Qi Injection and Xiang Dan Injection increased by 85.4% and 105.7% to RMB20,870,000 and RMB30,334,000 respectively. But sales of Shu Xue Ning Injection and Dan Shen Injection declined by 14.7% and 30.8% to RMB94,520,000 and RMB37,693,000 respectively during the Period.

Chinese medicine injections of the Group have regained growth momentum since 2021 and have thus far been on a continuous growth trend for three consecutive years. With the acceleration of population aging, the demand for Chinese medicine injections for cardio-cerebrovascular diseases will become more prominent.

### **Exclusive Oral Prescription Products – the Second Echelon in Leading Continuous Growth**

In the first six months of the year, the Group's exclusive products maintained its growth momentum in sales, and were the second echelon in leading the Group's continuous growth. Among them, sales of Huamoyan Granule, Qi Huang Tong Mi Soft Capsule, Jiang Zhi Tong Luo Soft Capsule, and Dan Deng Tong Nao Soft Capsule for the Period increased by 18.9%, 24.1%, 33.2% and 12.2% to RMB127,510,000, RMB38,008,000, RMB22,150,000 and RMB15,670,000 respectively as compared to the same period last year.

Huamoyan Granule is the only innovative Chinese Medicine for treating knee joint synovitis approved by the National Medical Products Administration. It has filled the gap in both Western medicines and TCM in the treatment of synovitis in China. Qi Huang Tong Mi Soft Capsule is the only next-generation modern Chinese medicine on the market for treating functional constipation in the elderly that is laxative without causing diarrhea, while also being sustainable and effective. Jiang Zhi Tong Luo Soft Capsule is the only lipid-regulating medication with a hepato-protective effect and can effectively treat hyperlipidemia with good safety.

The Group will continue to actively strengthen evidence-based medical research, and through boosting terminal investments and academic promotion to expand the sales of our exclusive oral prescription products.

### **OTC Medications – Sales Increased by 72.6%**

The Group has a number of well-received OTC Medications with sustained growth potential, which are available at more than 300,000 retail pharmacies nationwide and key internet pharmacy platforms.

In the first six months of 2023, the overall sales of OTC Medications increased by 72.6% period on period, of which sales of Huo Xiang Zheng Qi Soft Capsule and Qing Kai Ling Soft Capsule increased significantly by 110.8% and 54.6% respectively. Meanwhile, the Group's series of OTC granules for treating respiratory diseases in children also recorded a growth of 24.0% during the Period.

Huo Xiang Zheng Qi Soft Capsule is the Group's exclusive dosage form of OTC pharmaceutical product, which recorded sales of RMB150,102,000 and accounted for 6.3% of the Group's overall sales during the Period, and has been listed on the National Essential Drug List and the National Reimbursement Drug List. It is used for the treatment of external wind-cold, internal dampness, headache and dizziness, gastric distension and pain, vomiting and diarrhea, gastrointestinal cold and other discomforts. Moreover, the Huo Xiang Zheng Qi medications have been recommended by the National Health Commission and the State Administration of Traditional Chinese Medicine for prevention and control of the pandemic for many times, and has become one of the general public's regularly used modern TCM.

Qing Kai Ling Soft Capsule, an exclusive oral product of the Group, is both an OTC and prescription medication which has preventive and therapeutic effects on respiratory system diseases caused by viruses (fever virus and epidemic virus). During the Period, it recorded sales of RMB45,954,000 and accounted for 1.9% of the overall sales of the Group. Qing Kai Ling Soft Capsule has been listed on the National Essential Drug List and National Reimbursement Drug List, and was selected into the diagnosis and treatment program by the Ministry of Health of the PRC for human transmitted Avian Flu and A (H1-N1) Flu during the H1N1 pandemic. It was also included in the list of recommended medications in a number of provincial treatment plans during the COVID-19 pandemic.

During the Period, the sales of the Group's OTC granules for the treatment of respiratory diseases in children accounted for 2.2% of the Group's overall sales. Among them, Pediatric Qing Fei Hua Tan Granule grew by 26.8% during the Period. Pediatric Qing Fei Hua Tan Granule has superb curative effect and has become a famous brand of medication for coughs in children.

The Group will continue to strengthen marketing efforts of pediatric granules and other popular OTC granule products to drive continued growth of its OTC Medications.

### **Exclusive Innovative Medicines – Continue to Accelerate Development**

Currently, the Group is undergoing a number of projects which will be progressively put on pharmaceutical and clinical trials, among which 3 exclusive innovative medications, namely Sailuotong Capsule, Q-B-Q-F Condensed Pill and JC Soft Capsule, are still undergoing Phase III clinical trials.

Sailuotong Capsule is a “Compound Chinese Medicine” developed with modern innovative technology. Different from TCM, medicative components of Compound Chinese Medicine are separated and purified from medicinal materials through a series of modern technological means and the molecular constitution of its medicative components is also clarified for further pharmacodynamics studies. After the efficacy of each component is identified, the components are then combined to form new medicines with higher efficacy. Unlike other TCM, Compound Chinese Medicine originated from traditions, but features a clear chemical composition and action mechanism which matches its clinical effect, marking this a major breakthrough of TCM modernization. Sailuotong Capsule is composed of medicative parts extracted from saffron, ginseng and ginkgo biloba leaf, solving the undefined material base and unclear action mechanism of TCM. Please refer to the interim reports and annual reports announced in previous years for the detailed descriptions and market potential of Sailuotong Capsule and the other two medications.

During the Period, the Group received approval for drug clinical trial from the National Medical Products Administration to carry out the clinical trial of “Yi Gong San Granules”, a class 1.1 innovative Chinese medicine developed by the Group. “Yi Gong San Granule” comes from the classical prescription of the Song Dynasty. It has been in clinical application for more than 900 years to treat anemia of chronic disease. At present, there is no specific Chinese patent medicine for treating anemia of chronic disease on the market. Studies have demonstrated the clinical efficacy of “Yi Gong San Granules” in the treatment of anemia of chronic disease, especially in cases where EPO therapy with erythropoietin is ineffective. “Yi Gong San Granules” will fill the market gap in the treatment of anemia of chronic disease to meet clinical needs and will show its great social value as well. The Group will provide updates on the status of its clinical trials from time to time.



## **Ancient Classical Prescriptions – Listing Application for Class 3.1 of New TCM**

The Group has been persistently committed to promoting the inheritance, development and innovation of TCM, and is on its way to develop over 100 new medications based on ancient classical prescriptions.

Classical prescriptions are TCM compounds originated from ancient classical prescriptions as recorded in ancient medical books, which are still broadly used nowadays with clear efficacy. The Group developed such classical prescriptions to standardized products for listing so that more people will be benefited therefrom. This year, the Group has already submitted two new product listing applications based on ancient classical prescriptions.

During the Period, the Group submitted the new product listing application for Shaoyao Gancao Decoction Granule (芍藥甘草湯顆粒) under Class 3.1 of TCM. Shaoyao Gancao Decoction Granule is based on an ancient classical prescription for relieving spasm and pain in various diseases characterized by muscle spasms and pain.

The Group also recently submitted a new product listing application for Yiguan Jian Granule (一貫煎顆粒) under Class 3.1 of new TCM. Yiguan Jian is an ancient classical prescription, while Yiguan Jian Granule is mainly used in the clinical treatment of chronic hepatitis, chronic gastritis, gastric and duodenal ulcers, intercostal neuralgia and neurosis, etc..

Class 3.1 of new TCM are TCM compounds managed under the catalogue of ancient classical prescriptions. In 2018, the State Administration of Traditional Chinese Medicine issued the “Ancient Classical Prescription Catalogue (First Batch)” (《古代經典名方目錄(第一批)》), featuring 100 ancient classical prescriptions. Such prescriptions are mainly extracted from some ancient medical books from the Han Dynasty to the Qing Dynasty, among which there are Shaoyao Gancao Decoction and Yiguan Jian.

On 5 July 2023, the Center for Drug Evaluation of the National Medical Products Administration issued the “Opinions on Accelerating the Communication and Registration of TCM Compounds in Ancient Classical Prescriptions (Consultation Draft)” (《關於加快古代經典名方中藥複方製劑溝通交流和申報的有關意見(徵求意見稿)》), aiming to promote the R&D and registration of TCM compounds within Class 3.1 of TCM managed under the catalogue of ancient classical prescriptions. Guided by national policies, the Group is accelerating the registration of several new drugs developed from ancient classical prescriptions of Chinese medicine under Class 3.1 of TCM, with the goal of completing the registration of the first batch of ancient classical prescription of Chinese medicines by the end of 2023.

## **China Continues to Introduce Policies to Support TCM**

On 25 August 2023, the State Council held an executive meeting to review and approve the “Pharmaceutical Industry High-Quality Development Action Plan (2023-2025)”. The meeting emphasized the need to focus on the characteristics of high level of difficulty, long cycle, and substantial investment in pharmaceutical R&D and innovation and to provide full-chain support, encourage and guide the development and growth of leading pharmaceutical companies in order to improve industrial concentration and market competitiveness. It is also necessary to utilize the unique advantages of Chinese medicines in our country, to increase its protection and to maintain a safe development of Chinese medicines.

The country’s continuous introduction of policies to support TCM will provide strong support for the development of the TCM industry and accelerate the pace of TCM inheritance and innovation.

## **FINANCIAL ANALYSIS**

### **Turnover**

For the first six months of 2023, the Group continued to produce modern Chinese medicine products of good efficacy and high quality. The Group’s turnover increased by 32.1% as compared to the corresponding period of last year. Sales of our injection products increased by 37.3% to RMB957,253,000, accounting for 39.9% of the Group’s total turnover. Sales of soft capsule products increased by 19.0% to RMB352,066,000, accounting for 14.7% of the Group’s total turnover. Sales of granule products increased by 28.5% to RMB331,191,000, accounting for 13.8% of the Group’s total turnover. Sales of TCM formula granules increased by 34.0% to RMB628,658,000, accounting for 26.2% of the Group’s total turnover. The Group also sold RMB129,512,000 of medicines in other formats which accounted for 5.4% of the Group’s turnover.

Sales of prescription and OTC medications of the Group for the first six months of 2023 were RMB2,056,849,000 and RMB341,831,000 respectively, which were equal to 85.7% and 14.3% of the Group’s turnover respectively.

### **Cost of Sales**

Cost of sales of the Group for the first six months of 2023 was RMB594,723,000, representing 24.8% of the Group’s turnover. In particular, direct materials, direct labour and other production costs accounted for 68.2%, 14.6% and 17.2% of the total production costs respectively (for the corresponding period of 2022: 60.5%, 15.5% and 24.0%).

## **Gross Profit Margin**

For the first six months of 2023, average gross margin of the Group's injection products, soft capsule products, granule products and TCM formula granule products were 77.2% (for the corresponding period of 2022: 73.6%), 75.9% (for the corresponding period of 2022: 74.6%), 77.8% (for the corresponding period of 2022: 77.5%) and 73.8% (for the corresponding period of 2022: 70.1%) respectively. Overall gross profit margin was 75.2% as compared to 73.0% of the corresponding period of last year.

## **Other Income**

Other income mainly included government subsidies of RMB8,812,000 (for the corresponding period of 2022: RMB7,634,000). The government subsidies mainly represented incentives received from the government for research activities and investments in the relevant regions in the PRC by the Group.

## **Investment Income**

Investment income mainly included interest income from bank deposits and structured deposits totaling RMB52,486,000 (for the corresponding period of 2022: RMB53,023,000) and interest income from investments in financial products of RMB4,123,000 (for the corresponding period of 2022: RMB3,504,000).

## **Other Gains and Losses**

Other gains and losses comprised net exchange gain and loss on disposal of property, plant and equipment. The Group recorded a net exchange gain of RMB7,054,000 (for the corresponding period of 2022: net exchange loss of RMB1,847,000) for the first six months of 2023, which was mainly resulted from the exchange gain arising from changes in exchange rate among Australian dollars, Hong Kong dollars and Renminbi. Besides, net loss on disposal of property, plant and equipment for this Period was RMB386,000 (for the corresponding period of 2022: net loss of RMB296,000).

## **Impairment Losses on Financial Assets**

In the first six months of 2023, respective impairment of RMB5,105,000 (for the corresponding period of 2022: RMB2,748,000) and of RMB1,131,000 (for the corresponding period of 2022: reversal of impairment of RMB1,305,000) for trade receivables and trade receivables backed by bank bills were accounted for after the expected credit risk of financial assets assessment by the Group's management. The increase in impairment of financial assets was mainly due to the overall increase in trade receivables and trade receivables backed by bank bills as compared to the corresponding period of last year.

## **Selling and Distribution Costs**

Selling and distribution costs for the first six months of 2023 increased by 24.3% from the corresponding period of last year and were equal to 42.7% (for the corresponding period of 2022: 45.4%) of the Group's turnover. The increase was mainly due to the increase in market development expenses, sale management expenses and market promotion expenses as compared to the same period of last year.

## **Administrative Expenses**

In the first six months of 2023, administrative expenses increased by approximately 8.1% as compared to the corresponding period of last year, representing approximately 5.8% (for the corresponding period of 2022: 7.0%) of the Group's turnover. Administrative expenses mainly comprised salaries and social security outlay of administration staff, depreciation expenses of property, plant and equipment and amortisation expenses of intangible assets which accounted for 2.1% and 1.1% (for the corresponding period of 2022: 2.3% and 1.5%) of the Group's turnover respectively.

## **Research and Development Costs**

During the first six months of 2023, research and development costs accounted for approximately 2.0% (for the corresponding period of 2022: 1.6%) of the Group's turnover.

## **Taxation**

Taxation for the first six months of 2023 amounted to RMB179,823,000 (for the corresponding period of 2022: RMB80,285,000). The effective tax rate increased from 19.5% in the corresponding period of last year to 26.8%. This was mainly due to the withholding tax related to dividend distributions of subsidiaries in the PRC during the Period.

## **Profit for the Period**

The Group's net profit for the first six months of 2023 was RMB491,465,000, representing an increase of 48.4% as compared to the corresponding period of last year. The rise in profit was mainly attributable to the increased turnover and operating profit during the Period.

## **Liquidity and Financial Resources**

As at 30 June 2023, bank balances and cash of the Group amounted to RMB5,364,576,000 (31 December 2022: bank balances and cash and structured deposits totaling RMB5,046,495,000) of which RMB5,101,762,000 (31 December 2022: RMB4,831,946,000), were denominated in Renminbi. Others being equivalent to RMB7,266,000, RMB251,870,000 and RMB3,678,000 (31 December 2022: RMB129,406,000, RMB81,618,000 and RMB3,525,000) were denominated in Hong Kong dollars, Australian dollars and United States dollars respectively.

The directors of the Company (the "Directors") believe that the financial position of the Group is healthy, with sufficient financial resources to meet the need for future development.

## **Property, Plant and Equipment**

In the first six months of 2023, the Group acquired land use rights of RMB66,301,000, plant and machinery of RMB30,720,000, office equipment of RMB1,861,000, owned properties of RMB765,000 and the addition to construction in progress amounted to approximately RMB10,523,000 in total. Besides, following the adoption of IFRS 16, property, plant and equipment had included the leasehold land, leasehold properties, leasehold motor vehicles and leasehold machineries which had respective net book values of RMB172,223,000, RMB1,200,000, RMB594,000 and RMB971,000 as at 30 June 2023.

For the six months ended 30 June 2023, depreciation for property, plant and equipment amounted to RMB77,208,000 as compared to RMB84,329,000 during the corresponding period of last year.

## **Interim Dividend**

The Board resolved to declare the second interim dividend of RMB11 cents per share amounting to RMB83,094,000 in respect of the fiscal year 2023 (calculated on the basis of 827,000,000 shares issued less 71,600,000 shares held for share award scheme as at 30 June 2023), which will be paid on 29 September 2023 to the shareholders whose names appear on the Company's register of members on 15 September 2023.

The above interim dividend will be payable in cash in Hong Kong dollars and will be converted from Renminbi at the telegraphic transfer exchange rates quoted by bank at 10:00 a.m. on 30 August 2023 (RMB1=HK\$1.071). Accordingly, the amount payable on 29 September 2023 will be HK\$0.118 per share.

## INTERIM RESULTS

The unaudited consolidated results of the Group for the six months ended 30 June 2023 together with the comparative figures for the six months ended 30 June 2022 are as follows:

### CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2023

	NOTES	Six months ended 30 June	
		2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Revenue	3	<b>2,398,680</b>	1,815,194
Cost of sales		<b>(594,723)</b>	(490,380)
Gross profit		<b>1,803,957</b>	1,324,814
Other income		<b>22,177</b>	15,434
Investment income		<b>56,609</b>	56,527
Other gains and losses		<b>6,668</b>	(2,143)
Impairment losses on financial assets under expected credit loss model, net of reversal	10	<b>(6,236)</b>	(1,443)
Selling and distribution costs		<b>(1,025,150)</b>	(824,798)
Administrative expenses		<b>(138,368)</b>	(127,967)
Research and development costs		<b>(48,198)</b>	(28,671)
Finance costs		<b>(171)</b>	(345)
Profit before taxation		<b>671,288</b>	411,408
Taxation	4	<b>(179,823)</b>	(80,285)
Profit and total comprehensive income for the period	5	<b><u>491,465</u></b>	<u>331,123</u>
Earnings per share	7		
Basic		<b><u>RMB65 cents</u></b>	<u>RMB44 cents</u>
Diluted		<b><u>RMB65 cents</u></b>	<u>RMB44 cents</u>

## CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 June 2023

	<i>NOTES</i>	<b>30.6.2023</b> <b>RMB'000</b> <b>(Unaudited)</b>	31.12.2022 <b>RMB'000</b> <b>(Audited)</b>
Non-current assets			
Property, plant and equipment	8	<b>1,239,511</b>	1,216,937
Intangible assets		<b>38,454</b>	47,348
Goodwill		<b>165,956</b>	165,956
Deferred tax assets		<b>17,437</b>	19,221
		<b><u>1,461,358</u></b>	<u>1,449,462</u>
Current assets			
Inventories		<b>799,301</b>	657,659
Trade receivables	9	<b>759,323</b>	673,380
Trade receivables backed by bank bills	9	<b>451,773</b>	301,682
Prepayments, deposits and other receivables		<b>66,079</b>	103,183
Structured deposits		–	20,230
Bank balances and cash		<b>5,364,576</b>	5,026,265
		<b><u>7,441,052</u></b>	<u>6,782,399</u>
Current liabilities			
Trade payables	11	<b>387,013</b>	308,540
Trade payables backed by bank bills	11	–	205
Other payables and accrued expenses		<b>1,195,111</b>	1,063,519
Bank borrowing		<b>300,000</b>	–
Contract liabilities		<b>65,087</b>	153,118
Lease liabilities		<b>3,607</b>	6,530
Amounts due to related companies		<b>13,784</b>	13,784
Deferred income		<b>14,780</b>	12,103
Tax payable		<b>97,267</b>	107,794
		<b><u>2,076,649</u></b>	<u>1,665,593</u>
Net current assets		<b><u>5,364,403</u></b>	<u>5,116,806</u>
Total assets less current liabilities		<b><u>6,825,761</u></b>	<u>6,566,268</u>

	<b>30.6.2023</b>	31.12.2022
	<b><i>RMB'000</i></b>	<i>RMB'000</i>
	<b>(Unaudited)</b>	(Audited)
Non-current liabilities		
Lease liabilities	<b>660</b>	912
Deferred tax liabilities	<b>22,670</b>	18,844
Deferred income	<b>162,614</b>	163,986
	<b>185,944</b>	183,742
Net assets	<b>6,639,817</b>	6,382,526
Capital and reserves		
Share capital	<b>87,662</b>	87,662
Reserves	<b>6,552,155</b>	6,294,864
Total equity	<b>6,639,817</b>	6,382,526



# NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

*For the six months ended 30 June 2023*

## 1. GENERAL

The condensed consolidated financial statements have been prepared in accordance with the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and International Accounting Standard 34 “Interim Financial Reporting” issued by International Accounting Standards Board.

The Group’s condensed consolidated financial statements are presented in Renminbi (“RMB”) which is also the functional currency of the Company.

## 2. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis.

The accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2023 are the same as those presented in the Group’s annual consolidated financial statements for the year ended 31 December 2022.

### **Application of amendments to International Financial Reporting Standards (“IFRS Standards”)**

In the current interim period, the Group has applied the following amendments to IFRS Standards issued by the International Accounting Standards Board for the first time, which are mandatorily effective for the Group’s annual period beginning on 1 January 2023 for the preparation of the Group’s condensed consolidated financial statements:

IFRS 17 (including the October 2020 and February 2022 Amendments to IFRS 17)	Insurance Contracts
Amendments to IAS 8	Definition of Accounting Estimates
Amendments to IAS 12	Deferred Tax related to Assets and Liabilities arising from a Single Transaction
Amendments to IAS 12	International Tax Reform – Pillar Two Model Rules

The application of the amendments to IFRS Standards in the current interim period has had no material impact on the Group’s financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

### 3. REVENUE AND SEGMENT INFORMATION

#### Operating segment

The Group is engaged in a single operating segment in research and development, manufacturing and trading of Chinese pharmaceutical products. This operating segment has been identified on the basis of internal management reports that are regularly reviewed by the chairman of the board of directors of the Group, being the chief operating decision maker, for the purpose of resources allocation and performance assessment. No other discrete financial information is provided other than the Group's results and financial position as a whole. Accordingly, only entity-wide disclosures are presented.

#### Revenue from major products

The following is an analysis of the Group's revenue from its major products:

	Six months ended 30 June	
	2023 <i>RMB'000</i> (Unaudited)	2022 <i>RMB'000</i> (Unaudited)
Injections	957,253	697,146
Soft capsules	352,066	295,959
Granules	331,191	257,806
Traditional Chinese medicine formula granules	628,658	469,273
Others	129,512	95,010
	<u>2,398,680</u>	<u>1,815,194</u>

Sales of the Group to external customers were substantially made in the PRC including Hong Kong.

### 4. TAXATION

	Six months ended 30 June	
	2023 <i>RMB'000</i> (Unaudited)	2022 <i>RMB'000</i> (Unaudited)
PRC Enterprise Income Tax ("EIT"):		
Current tax	146,289	74,583
(Over) underprovision in prior years	(4,153)	3,132
Withholding tax on distributed profits of subsidiaries operating in the PRC	<u>32,077</u>	<u>—</u>
	174,213	77,715
Deferred tax	<u>5,610</u>	<u>2,570</u>
	<u>179,823</u>	<u>80,285</u>

Under the Law of the PRC on EIT (the “EIT Law”) and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% for both periods.

Certain subsidiaries which are operating in Western China have been granted tax concession by the local tax bureau and are entitled to PRC EIT at concessionary rate of 15% for both periods. Certain subsidiaries which are recognised as High and New-tech Enterprise have been granted tax concessions by the local tax bureau and are entitled to PRC EIT at concessionary rate of 15% for both periods. In addition, a subsidiary which is operating in agricultural products business has been granted tax exemption by the local tax bureau.

According to a joint circular of the State Taxation Administration, Cai Shui 2011 No. 1, PRC withholding income tax of 10% shall be levied on the dividend declared by the companies established in the PRC to their foreign investors out of their profits earned after 1 January 2008. A lower 5% withholding tax rate may be applied when the immediate holding companies of the PRC subsidiaries are incorporated or operated in Hong Kong and fulfil the requirements to the tax treaty arrangements between the PRC and Hong Kong. Those immediate holding companies of the Group’s PRC subsidiaries were entitled to 5% withholding tax rate during both periods.

Under the EIT Law, withholding tax is imposed on dividends declared in respect of profits earned by PRC subsidiaries from 1 January 2008 onwards. Deferred taxation has not been provided for in the condensed consolidated financial statements in respect of temporary differences attributable to accumulated undistributed profits of the PRC subsidiaries amounting to RMB4,672,808,000 (31 December 2022: RMB4,843,786,000) as the Group is able to control the timing of the reversal of the temporary differences and it is probable that the temporary differences will not be reversed in the foreseeable future.

## 5. PROFIT FOR THE PERIOD

### Six months ended 30 June

2023	2022
<i>RMB’000</i>	<i>RMB’000</i>
(Unaudited)	(Unaudited)

Profit for the period has been arrived at after charging (crediting):

Amortisation of intangible assets	<b>8,894</b>	9,539
Depreciation of property, plant and equipment	<b>77,208</b>	84,329
Government subsidies (included in other income) ( <i>Note</i> )	<b>(8,812)</b>	(7,634)
Net exchange (gain) loss (included in other gains and losses)	<b>(7,054)</b>	1,847
Loss on disposal of property, plant and equipment (included in other gains and losses)	<b>386</b>	296
	<b><u>386</u></b>	<b><u>296</u></b>

*Note:* The government subsidies represent the amounts received from the local government by the subsidiaries of the Company.

During the six months ended 30 June 2023, government subsidies of (a) RMB5,405,000 (six months ended 30 June 2022: RMB854,000) represent incentives received in relation to engagement of the subsidiaries of the Company in high technology business. The grants were unconditional, approved and received during the year of recognition; and (b) RMB3,407,000 (six months ended 30 June 2022: RMB6,780,000) represent recognition of deferred income upon completion of related research activities and development projects.

## 6. DIVIDENDS

	<b>Six months ended 30 June</b>	
	<b>2023</b> <i>RMB'000</i> <b>(Unaudited)</b>	<b>2022</b> <i>RMB'000</i> <b>(Unaudited)</b>
Dividends recognised as distribution during the periods:		
– 2022 first interim dividend of RMB21 cents per share	–	158,634
– 2023 first interim dividend of RMB31 cents per share	<u>234,174</u>	<u>–</u>
	<u><b>234,174</b></u>	<u>158,634</u>
Dividends declared subsequent to the reporting periods:		
– 2022 second interim dividend of RMB11 cents per share	–	83,094
– 2023 second interim dividend of RMB11 cents per share	<u>83,094</u>	<u>–</u>
	<u><b>83,094</b></u>	<u>83,094</u>

The 2023 second interim dividend of RMB11 cents per share, in the amount of an aggregate of RMB83,094,000, has been declared by the directors of the Company on 30 August 2023 and will be paid out on 29 September 2023, to the shareholders of the Company whose names appear on the register of the members of the Company on 15 September 2023. The aggregate amount of RMB83,094,000 (six months ended 30 June 2022: RMB83,094,000) has been calculated on the basis of 827,000,000 (2022: 827,000,000) shares in issue less 71,600,000 (2022: 71,600,000) shares held for share award scheme as at 30 June 2023.

## 7. EARNINGS PER SHARE

The calculation of basic and diluted earnings per share attributable to the owners of the Company is based on the following data:

	<b>Six months ended 30 June</b>	
	<b>2023</b> <i>RMB'000</i> <b>(Unaudited)</b>	<b>2022</b> <i>RMB'000</i> <b>(Unaudited)</b>
Profit for the period attributable to the owners of the Company for the purpose of basic and diluted earnings per share	<u>491,465</u>	<u>331,123</u>
	<b>Six months ended 30 June</b>	
	<b>2023</b>	<b>2022</b>
Weighted average number of ordinary shares in issue less shares held for share award scheme for the purpose of calculation of basic and diluted earnings per share	<u>755,400,000</u>	<u>755,400,000</u>

During the six months ended 30 June 2022, the computation of diluted earnings per share did not assume the exercise of the Company's options at exercise prices of HK\$8.39 and HK\$7.21 because the exercise prices of those options were higher than the average market price for shares for the six months ended 30 June 2022.

## 8. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2023, the Group made additions to construction in progress of RMB10,523,000 (six months ended 30 June 2022: RMB34,015,000) and acquired a land use right of RMB66,301,000 and other property, plant and equipment of RMB33,346,000 (six months ended 30 June 2022: RMB18,964,000). During the six months ended 30 June 2023, the Group also disposed of certain property, plant and equipment with carrying amount of RMB10,388,000 (six months ended 30 June 2022: RMB1,066,000) at net consideration of RMB10,002,000 (six months ended 30 June 2022: RMB770,000), resulting in a loss on disposal of RMB386,000 (six months ended 30 June 2022: RMB296,000).

## 9. TRADE RECEIVABLES/TRADE RECEIVABLES BACKED BY BANK BILLS

	<b>30.6.2023</b> <i>RMB'000</i> <b>(Unaudited)</b>	31.12.2022 <i>RMB'000</i> (Audited)
Trade receivables	<b>790,113</b>	699,065
Less: Allowance for expected credit loss ("ECL")	<u><b>(30,790)</b></u>	<u>(25,685)</u>
	<u><b>759,323</b></u>	<u>673,380</u>
Trade receivables backed by bank bills	<b>454,012</b>	302,790
Less: Allowance for ECL	<u><b>(2,239)</b></u>	<u>(1,108)</u>
	<u><b>451,773</b></u>	<u>301,682</u>
	<u><b>1,211,096</b></u>	<u>975,062</u>

The Group allows a credit period normally ranging from six months to one year to its trade customers. The following is an aged analysis of the trade receivables and trade receivables backed by bank bills, net of allowance for ECL, presented based on the invoice date at the end of the reporting period, which approximated the respective revenue recognition dates.

	<b>30.6.2023</b>	31.12.2022
	<b><i>RMB'000</i></b>	<i>RMB'000</i>
	<b>(Unaudited)</b>	(Audited)
Within 6 months	<b>1,012,559</b>	811,052
Over 6 months but less than 1 year	<b>146,434</b>	117,855
Over 1 year but less than 2 years	<b>46,233</b>	40,546
More than 2 years	<b>5,870</b>	5,609
	<b><u>1,211,096</u></b>	<u>975,062</u>

As at 30 June 2023, total bills received with carrying amount of RMB451,773,000 (31 December 2022: RMB301,682,000) are held by the Group for future settlement of trade receivables. All bills received by the Group are with a maturity period of less than one year.

#### **10. IMPAIRMENT LOSSES ON FINANCIAL ASSETS UNDER EXPECTED CREDIT LOSS MODEL, NET OF REVERSAL**

	<b>Six months ended 30 June</b>	
	<b>2023</b>	2022
	<b><i>RMB'000</i></b>	<i>RMB'000</i>
	<b>(Unaudited)</b>	(Unaudited)
Impairment losses recognised on trade receivables	<b>5,105</b>	2,748
Impairment losses recognised (reversed) on trade receivables backed by bank bills	<b>1,131</b>	(1,305)
	<b><u>6,236</u></b>	<u>1,443</u>

The basis of determining the inputs and assumptions and the estimation techniques used in the condensed consolidation financial statements for the six months ended 30 June 2023 are the same as those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2022.

## 11. TRADE PAYABLES

	<b>30.6.2023</b> <b>RMB'000</b> <b>(Unaudited)</b>	31.12.2022 <b>RMB'000</b> <b>(Audited)</b>
Trade payables	<b>387,013</b>	308,540
Trade payables backed by bank bills ( <i>Note</i> )	<u>–</u>	<u>205</u>
	<b><u>387,013</u></b>	<b><u>308,745</u></b>

*Note:* These related to trade payables in which the Group had issued bills to the relevant suppliers for future settlement of trade payables. The Group continued to recognise these trade payables as the Group was obliged to make payments on due dates of the bills.

An aged analysis of the Group's trade payables presented based on the invoice date at the end of the reporting period is as follows:

	<b>30.6.2023</b> <b>RMB'000</b> <b>(Unaudited)</b>	31.12.2022 <b>RMB'000</b> <b>(Audited)</b>
Within 6 months	<b>378,363</b>	298,906
Over 6 months but less than 1 year	<b>3,131</b>	3,793
Over 1 year but less than 2 years	<b>1,220</b>	2,363
Over 2 years but less than 3 years	<b>1,454</b>	254
Over 3 years	<u><b>2,845</b></u>	<u>3,429</u>
	<b><u>387,013</u></b>	<b><u>308,745</u></b>

The average credit period taken for trade purchases ranges from two months to six months.

## 12. SHARE-BASED PAYMENT TRANSACTIONS

### Share option scheme

The Company has a share option scheme which was adopted at the extraordinary general meeting of the Company held on 29 May 2015 for a period of 10 years. As at 30 June 2023, there is no outstanding share option under the share option scheme of the Company. During the period, no share options were granted under the share option scheme of the Company.

### Share award scheme

On 26 March 2018, the Company adopted the share award scheme ("the Scheme") with objectives to recognise the contributions by certain employees and give incentives thereto in order to motivate them for the continual operation and development of the Group; and to attract suitable personnel for further development of the Group. The Scheme does not constitute a share option scheme or an arrangement analogous to a share option scheme for the purpose of Chapter 17 of the Listing Rules. Unless terminated earlier by the board of directors pursuant to the Scheme, the Scheme shall be valid and effective for a period of ten years commencing on the adoption date.

Pursuant to the Scheme, the board of directors may, from time to time, at its absolute discretion cause to be paid to the trustee sums of money from the Company's resources for the purchase of shares to be held on trust in accordance with the Scheme and the trust deed. Such sums of money shall be applied towards the purchase of the specific number of shares from the open market according to the written instructions of the board of directors. The board of directors shall not make any further award which will result in the number of shares awarded by the board of directors under the Scheme exceeding 10% of the issued share capital of the Company as at the adoption date. The maximum aggregate number of the awarded shares which may be awarded to a selected employee under the Scheme shall not exceed 1% of the issued share capital of the Company as at the adoption date.

No shares were granted to eligible employees pursuant to the share award scheme. There were no disposal or purchase of shares by the trustee during the six months ended 30 June 2023 and 2022. At the end of the reporting period, there are 71,600,000 (31 December 2022: 71,600,000) shares held by the trustee.

### 13. RELATED PARTY DISCLOSURES

Other than as disclosed elsewhere in the condensed consolidated financial statements, the Group has following transactions and balances with related parties:

Name of related parties	Nature of transactions	Six months ended 30 June	
		2023 RMB'000 (Unaudited)	2022 RMB'000 (Unaudited)
Shineway Medical Science & Technology Co., Ltd. ("Shineway Medical")	Interest expenses on lease liabilities	105	220
	Service fee	5,525	5,215
	Hotel service fee	684	–
Shineway (Sanhe) Property Development Limited ("Shineway Sanhe")	Interest expenses on lease liabilities	25	53
	Service fee	1,354	1,278
Kang Yue Hotel Co., Ltd. ("Kang Yue Hotel")	Interest expenses on lease liabilities	–	60
Shijiazhuang Municipal Luancheng County Shineway Training School ("Shineway Training School")	Service fee	253	460
		30.6.2023 RMB'000 (Unaudited)	31.12.2022 RMB'000 (Audited)
Shineway Medical Shineway Sanhe	Lease liabilities	2,446	4,834
	Lease liabilities	589	1,164

Shineway Medical, Shineway Sanhe, Kang Yue Hotel and Shineway Training School are ultimately controlled by the controlling shareholder of the Company.



## Compensation of key management personnel

Key management personnel is deemed to be the members of the board of directors of the Company which has responsibility for planning, directing and controlling the activities of the Group. Details of the remuneration paid to them during the period were as follows:

	Six months ended 30 June	
	2023	2022
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Short-term benefits	6,421	6,400
Post-employment benefits	<u>47</u>	<u>23</u>
	<u><b>6,468</b></u>	<u><b>6,423</b></u>

## 14. CAPITAL COMMITMENTS

	30.6.2023	31.12.2022
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Audited)
Capital expenditure in respect of acquisition of property, plant and equipment contracted for but not provided in the condensed consolidated financial statements	<u><b>134,980</b></u>	<u><b>166,666</b></u>

## **OTHER INFORMATION**

### **CLOSURE OF SHARE TRANSFER REGISTRATION**

The register of members of the Company will be closed from 14 September 2023 to 15 September 2023 (both days inclusive). In order to qualify for the second interim dividend for the fiscal year 2023, all transfer documents accompanied by the relevant share certificates, must be lodged with the Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited at Shops 1712-16, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, not later than 4:30 p.m. on 13 September 2023.

### **PURCHASE, SALE OR REDEMPTION OF SECURITIES**

During the six months ended 30 June 2023, neither the Company nor any of its subsidiaries purchased, sold or redeemed any securities of the Company.

### **COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE**

The Company has complied with the code provisions set out in the Corporate Governance Code (the "Code") contained in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") during the six months ended 30 June 2023, except for code provision C.2.1 as described below.

Code provision C.2.1 of the Code stipulates that the roles of chairman of the board (the "Chairman") and chief executive should be separate and should not be performed by the same individual. The division of responsibilities between the Chairman and chief executive should be clearly established and set out in writing. The Company does not use the title "Chief Executive". The duty of the chief executive has been assumed by the president of the Company (the "President").

Mr. Li Zhenjiang has been both the Chairman and President. His responsibilities are clearly set out in writing and approved by the Board. Given the Group's current stage of development, the Board considers that vesting the roles of Chairman and President in the same person facilitates the execution of the Group's business strategies and maximizes effectiveness of its operations. The Board shall nevertheless review the relevant structure from time to time and shall consider any appropriate adjustments should new circumstances arise.

## **COMPLIANCE WITH THE MODEL CODE**

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (“Model Code”) as set out in Appendix 10 to the Listing Rules as the code of conduct regarding securities transactions by directors of the Company on terms no less exacting than the required standard set out in the Model Code. The prohibitions on securities dealing and disclosure requirements in the Model Code apply to specified individuals including the Group’s senior management and also persons who are privy to price sensitive information of the Group. Having made specific enquiry, all directors of the Company confirmed that they had complied with the required standard set out in the Model Code regarding securities transactions of the directors for the six months ended 30 June 2023.

## **AUDIT COMMITTEE**

The audit committee of the Company has reviewed with management and external auditors the accounting principles and policies adopted by the Group and the unaudited consolidated results of the Group for the six months ended 30 June 2023.

## **INTERIM REPORT**

The interim report of 2023 will be despatched to the shareholders of the Company and published on the website of The Stock Exchange of Hong Kong Limited ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company’s website ([www.shineway.com.hk](http://www.shineway.com.hk)) in due course.

We are delighted by the trust and support of our shareholders and those who care about the development of the Company. On behalf of the Board, we would like to take this opportunity to thank all of you, as well as our employees who made tremendous efforts.

By order of the Board  
**China Shineway Pharmaceutical Group Limited**  
**Li Zhenjiang**  
*Chairman*

Hong Kong, 30 August 2023

*As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Liu Tiejun; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Mr. Liu Shun Fai, Mr. Yew Yat On and Ms. Wang Guihua.*